GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action.

Front Endocrinol (Lausanne)

Cardiovascular and Metabolic Disease Research, Janssen Research & Development, Spring House, PA, United States.

Published: January 2022

The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein-coupled receptor (GPCR) whose activation results in suppression of food intake and improvement of glucose metabolism. Several receptor interacting proteins regulate the signaling of GLP-1R such as G protein-coupled receptor kinases (GRK) and β-arrestins. Here we evaluated the physiological and pharmacological impact of GRK inhibition on GLP-1R activity leveraging small molecule inhibitors of GRK2 and GRK3. We demonstrated that inhibition of GRK: i) inhibited GLP-1-mediated β-arrestin recruitment, ii) enhanced GLP-1-induced insulin secretion in isolated islets and iii) has additive effect with dipeptidyl peptidase 4 in mediating suppression of glucose excursion in mice. These findings highlight the importance of GRK to modulate GLP-1R function and . GRK inhibition is a potential therapeutic approach to enhance endogenous and pharmacologically stimulated GLP-1R signaling.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160450PMC
http://dx.doi.org/10.3389/fendo.2021.652628DOI Listing

Publication Analysis

Top Keywords

grk inhibition
12
glucagon-like peptide-1
8
grk
5
glp-1r
5
inhibition potentiates
4
potentiates glucagon-like
4
peptide-1 action
4
action glucagon-like
4
receptor
4
peptide-1 receptor
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!